RET kinase inhibitors therapy(KinaRx)

N/A

Report date: 2024/07/08 17:21:13
NME

Base Information

Drug NameRET kinase inhibitors therapy(KinaRx)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Carcinoma, Non-Small-Cell LungEndocrine Gland Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKinaRx Inc
China Registration ClassN/A

Develop Information

Active CompaniesKinaRx Inc
Inactive CompaniesN/A
Active IndicationsMedullary thyroid cancer (MTC)Carcinoma, Non-Small-Cell LungEndocrine Gland Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A